THE ROLE OF THE PHARMACIST IN ADHERENCE AND SAFETY OF COMBINED DOLUTEGRAVIR/LAMIVUDINE THERAPY

Abstract

Introduction: Human Immunodeficiency Virus (HIV), infection remains a significant public health problem, requiring effective therapeutic strategies for disease control and improvement of patients’ quality of life. Antiretroviral therapy has played a fundamental role in reducing HIV-related morbidity and mortality, with the combination of Dolutegravir and Lamivudine standing out as an effective, safe, and less complex therapeutic alternative. However, treatment adherence still represents one of the main challenges for the success of pharmacotherapy, potentially compromising viral load control and contributing to disease progression. Methods: This study aimed to analyze, through scientific literature, the contribution of the pharmacist to adherence and safety in the combined therapy of Dolutegravir and Lamivudine in patients living with HIV. It is a qualitative, descriptive, and exploratory study conducted through a bibliographic review of scientific databases, analyzing studies published between 2023 and 2026. Results: The results show that pharmaceutical care significantly contributes to improving treatment adherence, increasing therapeutic safety, and optimizing clinical outcomes, reinforcing the importance of this professional in comprehensive patient care. Conclusion: Therefore, it is essential that pharmacists act to ensure that the Dolutegravir/Lamivudine combined therapy is used as safely and effectively as possible, positively impacting clinical outcomes. Their role promotes more rational use of medications, minimizes risks, and strengthens the relationship with the patient.